Biotechnology market in Asia-Pacific region looks very lucrative from investment perspective

19 January 2011

The biotechnology industry in the Asia-Pacific region is attracting more and more private investments in the wake of immense growth opportunities and vast untapped biotech markets, according to a new report from RNCOS titled Asia Pacific Biotechnology Market (2008-2012).

Identifying the future growth potential of the industry, the governments of different countries in the Asia-Pacific region are taking up various initiatives to promote research in this region. Overall, the Asia-Pacific biotech market is expected to spur future growth in the global biotechnology market.

16% CAGR forecast over 2010-2012

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >